The Auxiliary Board of Northwestern Memorial Hospital Designates New Cause
By Megan McCannNews April 26, 2013
“The Auxiliary Board plays a unique role at Northwestern Memorial Hospital as a key sponsor of diverse, innovative research designed to address contemporary medical issues,” said Mindy Kurlansky, board president. “This is an exciting time of year for the Board. We are pleased to announce our new cause and look forward to another great Summer Lovin’ with our partner, Chicago magazine.”
The group has pledged its support to an innovative research study in bone marrow transplant, led by John Galvin, MD, hematopoietic stem cell transplant fellow at Northwestern Memorial. Bone marrow transplant, also called hematopoietic stem cell transplant (HSCT), is the only chance for a cure in many types of blood cancers. However, success is limited by a common and sometimes fatal complication in which the donor cells begin to attack the host. This complication is called graft-versus-host disease (GVHD). The current method used to prevent GVHD is long term immunosuppressive therapy, which carries an additional risk of infection for the patient.
“Our research team will attempt to prevent GVHD by inducing a specific tolerance within the donor cells—instead of inhibiting the patient’s whole immune system,” said Galvin. “If this novel approach proves successful, it could result in a safer stem cell transplant, making this important treatment accessible to a greater number of patients with blood cancers.”
To learn more about becoming a member or supporter of The Auxiliary Board, or for event information contact Jamal Bowleg at Northwestern Memorial Foundation at 312.926.4530.
For more information on cancer care at Northwestern Memorial, visit the hematology/oncology program website.